SCHEMBL20147678

SCHEMBL20147678

CC(C)NC(=O)NC1(C)CCN(C(C)C)CC1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.34
CYP2C9 P11712 2/20 0.34
HRH3 Q9Y5N1 2/20 0.33
SIGMAR1 Q99720 1/20 0.33
RET P07949 1/20 0.33
CCR1 P32246 1/20 0.33
CYP2D6 P10635 4/20 0.33
CYP2C19 P33261 1/20 0.33
MMP1 P03956 1/20 0.32
MMP9 P14780 1/20 0.32
MMP13 P45452 1/20 0.32
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALDH1A1 P00352 3/20 0.31
EPHX2 P34913 1/20 0.31
CHRM5 P08912 1/20 0.30
CHRM3 P20309 1/20 0.30
TACR2 P21452 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068867 0.84 CYP1A2 (0.35) CYP1A2CYP2C9SIGMAR1RETCCR1
SCHEMBL17034775 0.83 EPHX2 (0.37) CYP1A2CYP2C9CYP2D6CYP2C19MMP1
SCHEMBL16304087 0.80 DRD2 (0.37) HRH3CYP2D6MMP1MMP9MMP13
SCHEMBL13684410 0.80 EPHX2 (0.35) CYP1A2CYP2C9MMP1MMP9SMN1; SMN2
SCHEMBL20147679 0.79 EPHX1 (0.37) RETCYP2D6CYP2C19MMP1MMP9
SCHEMBL18705063 0.79 MMP9 (0.33) HRH3RETCYP2D6MMP1MMP9
SCHEMBL20147531 0.78 MMP9 (0.34) HRH3SIGMAR1RETCYP2D6MMP1
SCHEMBL20201374 0.76 MMP1 (0.32) HRH3SIGMAR1CYP2D6MMP1MMP9
SCHEMBL20147532 0.76 MMP9 (0.35) HRH3RETCYP2D6MMP1MMP9
SCHEMBL20147475 0.76 CCR1 (0.34) CYP2C9HRH3SIGMAR1CCR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CYP1A2 4287/4885CYP2C9 4195/4885HRH3 1000/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CYP1A2 4287/4885CYP2C9 4195/4885HRH3 1000/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CYP1A2 4287/4885CYP2C9 4195/4885HRH3 1000/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CYP1A2 4287/4885CYP2C9 4195/4885HRH3 1000/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CYP1A2 4287/4885CYP2C9 4195/4885HRH3 1000/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CYP1A2 4287/4885CYP2C9 4195/4885HRH3 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.